Back to search results

Study for EBV-Associated Nasopharyngeal Carcinoma

This study is testing a new treatment approach for Epstein-Barr Virus (EBV) associated nasopharyngeal carcinoma (a type of head and neck cancer). It combines chemotherapy drugs, Gemcitabine and Docetaxel, with an investigational drug called Toripalimab, followed by radiation therapy. Researchers want to see how safe and effective this combination is. You might be able to join if you have locally advanced EBV-positive nasopharyngeal carcinoma and haven't had prior treatment for it. The study will measure how many participants complete the induction chemotherapy and radiation treatments. The current recruitment status is unclear, and the study plans to enroll 24 participants.

Study design
This is an interventional study, but the phase is not specified. It plans to enroll 24 participants.
What's involved
Participants will receive Toripalimab intravenously every three weeks for 3 cycles, then for 9 cycles after radiation. They will also receive radiation therapy with cisplatin.
Compensation
Not stated in the trial record.
Follow-up
The study will track participants for 3 years to measure completion rates of induction chemotherapy and radiation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06592599

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Stanford University
~24 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:ToripalimabConcurrent Chemoradiation and Adjuvant treatment following Chemoradiation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Induction chemotherapy completion rate
Measured over 3 years
+1 more outcome measured

Conditions

Nasopharyngeal Carcinoma

Explore related trials

Nasopharyngeal CarcinomaX-linked Lymphoproliferative Syndrome 1

NCT06592599

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Stanford University

    Palo Alto, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • A. Dimitrios Colevas, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Elizabeth Winters
[email protected]
(650) 723-6372
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy;
Unstable angina and/or uncontrolled congestive heart failure within past 6 months;
Myocardial infarction within the last 6 months;
Current acute bacterial or fungal infection requiring intravenous antibiotics; note that patients receiving IV antibiotics or currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible.
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to day 1 of treatment; 8. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive 9. Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss that is tumor-related is allowed 10. ≥ grade 2 peripheral sensory neuropathy

What this trial measures

  • Induction chemotherapy completion rate3 years

    Induction chemotherapy completion rate, defined as the proportion of patients who complete three cycles of chemoimmunotherapy within 12 weeks of initiation. Completion is defined for induction as receiving all 3 cycles as planned, including protocol specified dose reduction and delays. .

  • Radiation completion rate3 years

    Radiation completion rate, defined as the proportion of patients who complete specified radiation within 8 weeks of radiation initiation. Radiation completion is defined as completion of planned doses of radiation.